Advances in Neurocardiology: Focus on Anticoagulation for Valvular Heart Disease With and Without Atrial Fibrillation.
作者信息
Gurol M Edip, Sposato Luciano A
机构信息
Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston (M.E.G.).
Departments of Clinical Neurological Sciences, Anatomy and Cell Biology, and Epidemiology and Biostatistics, Schulich School of Medicine and Dentistry (L.A.S.), Western University, London, ON, Canada.
出版信息
Stroke. 2022 Dec;53(12):3763-3768. doi: 10.1161/STROKEAHA.122.039310. Epub 2022 Nov 7.
Abstract
摘要
相似文献
1
Advances in Neurocardiology: Focus on Anticoagulation for Valvular Heart Disease With and Without Atrial Fibrillation.神经心脏病学进展：聚焦于伴或不伴心房颤动的瓣膜性心脏病的抗凝治疗
Stroke. 2022 Dec;53(12):3763-3768. doi: 10.1161/STROKEAHA.122.039310. Epub 2022 Nov 7.
2
[Antithrombotic treatment of patients with valvular atrial fibrillation].[瓣膜性心房颤动患者的抗栓治疗]
Ugeskr Laeger. 2017 Jul 17;179(29).
3
Use of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Lesions.直接口服抗凝剂在心房颤动合并心脏瓣膜病变患者中的应用。
J Am Heart Assoc. 2016 Feb 18;5(2):e002776. doi: 10.1161/JAHA.115.002776.
4
Optimal anticoagulation therapy in patients with valvular heart disease or atrial fibrillation.
Arch Intern Med. 2009 Nov 23;169(21):2032-3; author reply 2033. doi: 10.1001/archinternmed.2009.420.
5
"": Anticoagulation Management in Patients with Atrial Fibrillation and Prosthetic Valves in the Era of Direct Oral Anticoagulants.“”：直接口服抗凝剂时代的心房颤动和人工瓣膜患者的抗凝管理。
Medicina (Kaunas). 2019 Aug 4;55(8):437. doi: 10.3390/medicina55080437.
6
Can Direct Oral Anticoagulants Be Used for Stroke Prevention Among Patients with Valvular Atrial Fibrillation?直接口服抗凝剂可否用于预防瓣膜性心房颤动患者的卒中？
Curr Cardiol Rep. 2019 Aug 31;21(10):118. doi: 10.1007/s11886-019-1199-4.
7
Direct-acting oral anticoagulants in patients with atrial fibrillation and valvular heart disease.直接口服抗凝剂在心房颤动和心脏瓣膜病患者中的应用。
JAAPA. 2022 Sep 1;35(9):17-18. doi: 10.1097/01.JAA.0000854516.90788.a8.
8
Use of oral anticoagulants in complex clinical situations with atrial fibrillation.在伴有房颤的复杂临床情况下使用口服抗凝药物。
Med Clin (Barc). 2018 Jun;150 Suppl 1:8-24. doi: 10.1016/S0025-7753(18)30666-3.
9
Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Disease Other Than Significant Mitral Stenosis and Mechanical Valves: A Meta-Analysis.除重度二尖瓣狭窄和机械瓣膜外的心房颤动合并瓣膜性心脏病患者使用直接口服抗凝剂的荟萃分析。
Circulation. 2017 Feb 14;135(7):714-716. doi: 10.1161/CIRCULATIONAHA.116.026793.
10
Direct oral anticoagulant use in nonvalvular atrial fibrillation with valvular heart disease: a systematic review.直接口服抗凝药在合并心脏瓣膜病的非瓣膜性心房颤动中的应用：一项系统评价
Clin Cardiol. 2017 Jun;40(6):407-412. doi: 10.1002/clc.22659. Epub 2016 Dec 22.
引用本文的文献
1
Multimodal Cardiac Imaging in the Assessment of Patients Who Have Suffered a Cardioembolic Stroke: A Review.多模态心脏成像在评估心源性栓塞性卒中患者中的应用：综述
J Cardiovasc Dev Dis. 2023 Dec 31;11(1):13. doi: 10.3390/jcdd11010013.
本文引用的文献
1
Rivaroxaban in Rheumatic Heart Disease-Associated Atrial Fibrillation.利伐沙班在风湿性心脏病相关心房颤动中的应用。
N Engl J Med. 2022 Sep 15;387(11):978-988. doi: 10.1056/NEJMoa2209051. Epub 2022 Aug 28.
2
Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial.阿哌沙班与经导管主动脉瓣置换术后标准治疗的比较：ATLANTIS 试验。
Eur Heart J. 2022 Aug 1;43(29):2783-2797. doi: 10.1093/eurheartj/ehac242.
3
RIvaroxaban in mitral stenosis (RISE MS): A pilot randomized clinical trial.利伐沙班治疗二尖瓣狭窄（RISE-MS）：一项先导随机临床试验。
Int J Cardiol. 2022 Jun 1;356:83-86. doi: 10.1016/j.ijcard.2022.03.037. Epub 2022 Mar 16.
4
Non-vitamin K antagonist oral anticoagulants in patients with valvular heart disease.非维生素K拮抗剂口服抗凝剂用于心脏瓣膜病患者
Eur Heart J Suppl. 2022 Feb 14;24(Suppl A):A19-A31. doi: 10.1093/eurheartj/suab151. eCollection 2022 Feb.
5
Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR.TAVR术后艾多沙班与维生素K拮抗剂用于心房颤动的比较
N Engl J Med. 2021 Dec 2;385(23):2150-2160. doi: 10.1056/NEJMoa2111016. Epub 2021 Aug 28.
6
2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.2020 ACC/AHA 瓣膜性心脏病患者管理指南：执行摘要：美国心脏病学会/美国心脏协会联合临床实践指南委员会的报告。
Circulation. 2021 Feb 2;143(5):e35-e71. doi: 10.1161/CIR.0000000000000932. Epub 2020 Dec 17.
7
Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study.全球心血管疾病负担及危险因素, 1990-2019:来自 GBD 2019 研究的更新。
J Am Coll Cardiol. 2020 Dec 22;76(25):2982-3021. doi: 10.1016/j.jacc.2020.11.010.
8
Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve.利伐沙班在心房颤动合并生物瓣二尖瓣患者中的应用。
N Engl J Med. 2020 Nov 26;383(22):2117-2126. doi: 10.1056/NEJMoa2029603. Epub 2020 Nov 14.
9
Rivaroxaban Versus Warfarin in Patients with Mechanical Heart Valves: Open-Label, Proof-of-Concept trial-The RIWA study.机械心脏瓣膜患者中利伐沙班与华法林的比较：开放性、概念验证试验——RIWA 研究。
Am J Cardiovasc Drugs. 2021 May;21(3):363-371. doi: 10.1007/s40256-020-00449-3. Epub 2020 Nov 5.
10
Overestimation of Stroke Risk in Rheumatic Mitral Stenosis and the Implications for Oral Anticoagulation.风湿性二尖瓣狭窄中风风险的高估及其对抗凝治疗的影响
Circulation. 2020 Nov 3;142(18):1697-1699. doi: 10.1161/CIRCULATIONAHA.120.050347. Epub 2020 Nov 2.
Zotero 插件